- Conditions
- Binge Eating Behaviour, Eating Disorders, Physical Activity, Functional Magnetic Resonance Imaging (fMRI), Ecological Momentary Assessment, Loss of Control Eating
- Interventions
- Go/No-go task, Visual food task, Emotion regulation task
- Behavioral
- Lead sponsor
- The University of Texas at Dallas
- Other
- Eligibility
- 10 Years to 12 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2030
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Richardson, Texas • Fairfax, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 2,553
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus
- Interventions
- Insulin, Isophane, insulin glargine
- Drug
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Falls Church, Virginia
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 78
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
- Conditions
- Advanced Solid Tumors
- Interventions
- MEDI4736, tremelimumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 30
- States / cities
- Scottsdale, Arizona • Duarte, California • La Jolla, California + 23 more
- Conditions
- Tumor Pathway Activations Inhibited by Dovitinib
- Interventions
- Dovitinib (TKI258)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Pismo Beach, California + 43 more
- Conditions
- Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
- Interventions
- PRT2527
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Celebration, Florida • Sarasota, Florida + 4 more
- Conditions
- Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
- Interventions
- LAM-002A, Rituximab, Atezolizumab
- Drug
- Lead sponsor
- IRulya Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 11
- States / cities
- Huntsville, Alabama • Jacksonville, Florida • Atlanta, Georgia + 7 more
- Conditions
- BK Polyomavirus, Kidney Diseases
- Interventions
- FK778
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 21
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 15 more
- Conditions
- PreDiabetes, Cardiovascular Diseases
- Interventions
- Individualized Nutrition Therapy
- Other
- Lead sponsor
- George Mason University
- Other
- Eligibility
- 45 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- open-label rifaximin, double-blind placebo, double-blind rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 293
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 226 more
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
- Interventions
- furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy
- Drug
- Lead sponsor
- ArriVent BioPharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 69
- States / cities
- Daphne, Alabama • Yuma, Arizona • Fayetteville, Arkansas + 64 more
- Conditions
- Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Conventional Surgery, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Vincristine Sulfate Liposome
- Radiation · Procedure · Drug + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2026
- U.S. locations
- 199
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
- Conditions
- Premature Rupture of Membrane
- Interventions
- Erythromycin, Azithromycin
- Drug
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Falls Church, Virginia • Norfolk, Virginia
- Conditions
- HER2-positive Advanced Solid Tumor
- Interventions
- DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole
- Biological · Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 796 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 35
- States / cities
- Cerritos, California • Los Angeles, California • San Diego, California + 29 more
- Conditions
- Advanced Solid Tumors
- Interventions
- IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig, SC rilvegostomig + rHu
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia
- Conditions
- Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
- Interventions
- Pozelimab, Cemdisiran, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 975 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 158
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 125 more
- Conditions
- Extensive Stage-small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan, Atezolizumab, Carboplatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Biliary Tract Cancer
- Interventions
- Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 48
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Fullerton, California + 38 more
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- Osimertinib, Nivolumab, Telisotuzumab vedotin, Erlotinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 17 more
- Conditions
- Solid Tumor Malignancies
- Interventions
- KQB168, Pembrolizumab
- Drug
- Lead sponsor
- Kumquat Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 11 more
- Conditions
- Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC, Metastatic Colon Cancer, Colon Cancer, Advanced Colorectal Cancer
- Interventions
- CBI-1214
- Biological
- Lead sponsor
- Cartography Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 6 more
- Conditions
- Hepatitis C
- Interventions
- Telaprevir, Ribavirin, Pegylated interferon alfa 2a
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
- Conditions
- Tuberous Sclerosis, Lymphangioleiomyomatosis
- Interventions
- Phlebotomy, Buccal (cheek) swab, Genetic Testing, Tissue donation after routine clinical procedure
- Procedure · Genetic · Other
- Lead sponsor
- National Tuberous Sclerosis Association
- Other
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2050
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 19 more
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- MM-398, 5 Fluorouracil, Leucovorin
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 23
- States / cities
- Gilbert, Arizona • Glendale, Arizona • Scottsdale, Arizona + 20 more